Volume 11, Number 9—September 2005
Research
Dengue Virus Type 3, Brazil, 2002
Table 2
Investigation of suspected fatal dengue cases according to available clinical samples*
Clinical specimen | RT-PCR positive/studied (%) | Virus isolation positive/studied (%) | Serotype detected | MAC-ELISA positive/studied | Immunohistochemistry positive/studied | Confirmed cases/studied cases (%) |
---|---|---|---|---|---|---|
Serum | 15/42 | 4/38 | 15 DENV-3 | 18/42 | ND | 26/42 (61.9) |
CSF | 1/ 2 | 0/2 | 1 DENV-3 | 0/2 | ND | 1/2 |
Fresh tissues | 17/59 | 2/59 | 17 DENV-3 | ND | ND | 17/59(28.8) |
Formalin-fixed and paraffin embedded tissues | ND | ND | 0 | 0 | 23/48 | 23/48 (47.9) |
Total | 33/103 (32.0) | 6/99 (6.0) | 33 DENV-3 | 18/44 (40.9) | 23/48 (47.9) | 40/62† (64.5) |
*RT-PCR, reverse transcriptase–polymerase chain reaction; MAC-ELISA, immunoglobulin M antigen capture enzyme-linked immunosorbent assay; DENV, dengue virus; IgG, immunoglobulin G; ND, not done; CSF cerebrospinal fluid.
†Total of confirmed fatal cases by any method/total of fatal cases studied.